Foundayo vs. Wegovy vs. Zepbound: The Only Comparison That Matters in 2026
The first real oral GLP-1 just arrived. Here's how Foundayo stacks up against the two injectable giants on everything that matters: efficacy, convenience, cost, and who should choose what.
The Three-Way Race
The GLP-1 landscape changed permanently on April 1, 2026, when the FDA approved Foundayo (orforglipron) — the first oral GLP-1 with no food, water, or timing restrictions. For the first time, patients have a genuine choice between a daily pill and a weekly injection. This comparison breaks down exactly how each option performs across the metrics that actually matter.
Weight Loss: The Numbers
| Metric | Foundayo (orforglipron) | Wegovy (semaglutide) | Zepbound (tirzepatide) |
|---|---|---|---|
| Drug class | Oral small-molecule GLP-1 | Injectable peptide GLP-1 | Injectable dual GIP/GLP-1 |
| Weight loss at 72 weeks | 7.5–11.2% | 15.6–18.7%* | 19.5–22.5% |
| Key trial | ATTAIN-1 | STEP / STEP-UP | SURMOUNT-1 |
| Dosing | Once daily pill | Once weekly injection | Once weekly injection |
| Food/water restrictions | None | None (injection); 30-min fast (oral tablets) | None |
| Refrigeration required | No | Yes (pre-use) | Yes (pre-use) |
| FDA approved for weight loss | April 2026 | June 2021 | November 2023 |
*Wegovy 7.2mg (higher dose pending FDA approval) achieved 18.7% in the STEP-UP trial. Current max approved dose (2.4mg) achieves ~15.6%.
Convenience Factor
This is where Foundayo changes the calculus. No injection. No needle. No refrigerator. No timing your dose around meals. You take a pill whenever you want, with or without food, with or without water. For a medication many people will take for years or decades, this matters more than the clinical trials capture.
Both Wegovy and Zepbound require weekly subcutaneous injections. Many patients adapt to this quickly, but needle aversion remains a significant barrier — and the logistics of refrigerated medication make travel, commuting, and daily life more complicated.
Side Effect Profiles
All three share the same GI side effect profile (nausea, vomiting, diarrhea, constipation), with similar severity. However, there are notable differences:
| Side Effect | Foundayo | Wegovy | Zepbound |
|---|---|---|---|
| GI side effects (nausea, etc.) | Common | Common | Common |
| Injection site reactions | N/A | Possible | Possible |
| Discontinuation rate (trials) | Higher than placebo | ~7% (GI-related) | ~5–7% (GI-related) |
Cost Comparison
| Factor | Foundayo | Wegovy | Zepbound |
|---|---|---|---|
| List price | TBD (LillyDirect launch pricing) | ~$1,349/mo retail | ~$1,080/mo retail |
| Manufacturer savings | LillyDirect available | NovoCare savings card | LillyDirect vials from $399 |
| Medicare (July 2026+) | $50/mo (Bridge) | $50/mo (Bridge) | $50/mo (KwikPen only) |
| Compounded version available | No | Limited (enforcement pending) | Limited (enforcement pending) |
Who Each Drug Is Best For
You want maximum convenience (daily pill, no injection), hate needles, travel frequently, or want a brand-new medication with the fewest restrictions. Accept that you're trading approximately 5–10 percentage points of weight loss for a dramatically simpler daily routine.
You want maximum cardiovascular benefit (only GLP-1 with SELECT trial CV data), the broadest range of FDA-approved indications (CV risk, MASH, sleep apnea), and you're comfortable with weekly injections. The upcoming 7.2mg dose closes the efficacy gap with Zepbound.
Maximum weight loss is your priority. Zepbound's dual GIP/GLP-1 mechanism produces the highest weight loss numbers in clinical trials (up to 22.5%). If you're already comfortable with injections and want the most aggressive option, this is it.
Sources
- FDA. "FDA Approves First New Molecular Entity Under National Priority Voucher Program" (Foundayo). April 1, 2026. fda.gov
- Pharmacy Times. "FDA Approves Orforglipron, First GLP-1 Pill Without Time, Food, or Water Restrictions." April 2026. pharmacytimes.com
- Eli Lilly. "FDA approves Lilly's Foundayo (orforglipron)." Press release, April 2026. investor.lilly.com
- Prime Therapeutics. "GLP-1 Pipeline Update: February 2026." primetherapeutics.com
- CMS. "Medicare GLP-1 Bridge." cms.gov